Can US FDA Dodge DOGE? Return To Office Mandate May Be Biggest Hit

The incoming Trump Administration’s “Department Of Government Efficiency” has big plans for sweeping cuts to the federal bureaucracy and regulation. The US FDA likely will feel some effects, but could avoid the most damaging mandates.

(Shutterstock)
Michael McCaughan

Read more by Michael McCaughan

Michael McCaughan is a founding member of Prevision Policy LLC, a leading provider of regulatory and reimbursement policy analysis for the biopharma industry. He was previously the Editor-In-Chief of The Pink Sheet and remains a contributor to the publication.

More from Regulation

More from Wellness